Product Information
APIDRA SOLOSTAR 100 UNIT/ML is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $10.5010 per ML under NDC 00088250205. Its NADAC has been published 671 times since Nov 28, 2013.
Strength
100 [iU]/mL
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00088250205
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN GLULISINEApproval Type
Biologic (BLA)
FDA Application
BLA021629On Market Since
2/24/2009
Pharmacological Classes
Price Statistics
The NADAC for APIDRA SOLOSTAR 100 UNIT/ML has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 39.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.5010 per ML |
|---|---|
| All-time high | $35.3005 (Oct 16, 2019) |
| All-time low | $10.4984 (Apr 22, 2026) |
| 52-week high | $10.5222 |
| 52-week low | $10.4984 |
| Median price | $31.5707 |
| Average price | $27.1616 |
| Largest weekly change | -70.0% (Jan 3, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 22% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sanofi-Aventis U.S. LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
insulin glulisine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of APIDRA SOLOSTAR 100 UNIT/ML?
The current National Average Drug Acquisition Cost (NADAC) for APIDRA SOLOSTAR 100 UNIT/ML, manufactured by Sanofi-Aventis U.S. LLC, is $10.5010 per ML (NDC 00088250205), effective Sep 30, 2026.
How has the price of APIDRA SOLOSTAR 100 UNIT/ML changed over time?
Over the history we have for it, the NADAC for APIDRA SOLOSTAR 100 UNIT/ML has declined 39.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for APIDRA SOLOSTAR 100 UNIT/ML?
Since Nov 28, 2013, the NADAC for APIDRA SOLOSTAR 100 UNIT/ML has ranged from a low of $10.4984 (Apr 22, 2026) to a high of $35.3005 (Oct 16, 2019), with a median of $31.5707 per ML.
Are there cheaper alternatives to APIDRA SOLOSTAR 100 UNIT/ML?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, APIDRA 100 UNIT/ML VIAL, is $8.1623 per ML — about 22% below APIDRA SOLOSTAR 100 UNIT/ML.
Who manufactures APIDRA SOLOSTAR 100 UNIT/ML?
APIDRA SOLOSTAR 100 UNIT/ML (NDC 00088250205) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a brand product.